A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)

Izzo, I; Albini, L; Calabresi, A; Motta, D; Bellagamba, R; Fezza, R; Narciso, P; Sighinolfi, L; Maggi, P; Focà, E; Mendeni, M; Manili, L; Magoni, M; Carosi, G; Quiros-Roldan, E; Torti, C

doi:10.1186/1758-2652-13-S4-P85

Journal of the International AIDS Society

Article metrics
Last updated: Sun, 5 May 2024 9:30:24 Z

A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)

Access & Citations

854

Article Accesses
0

Web of Science
0

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.